Immune thrombocytopenic purpura following mRNA-SARS-CoV-2 vaccination: a case report
DOI:
https://doi.org/10.15649/cuidarte.3799Keywords:
COVID-19, SARS-CoV-2, mRNA Vaccines, Immune Thrombocytopenic Purpura, PlateletsAbstract
Highlights
- Cases of autoimmune diseases have been registered after vaccination with mRNA vaccines (BNT162b2 or mRNA-1273).
- A case of immune thrombocytopenic purpura following mRNA-SARS-CoV-2 without any previous reports of thrombocytopenia or other hematologic disorders is presented.
- The thrombocytopenia persisted and progressed to a chronic non-bleeding condition two years after the first vaccine dose administration, with episodes of temporary recovery of platelet counts.
- Considering that the incidence of secondary ITP and other hematological disorders has significantly increased due to COVID-19 vaccination, a post-vaccination hemogram check could be a useful and inexpensive follow-up measure.
Introduction: Herein, it is presented a case report of a Colombian adult male patient, without any previous report of thrombocytopenia or hematological disorders, who developed a mild and chronic paucisymptomatic immune thrombocytopenic purpura, a rare complication following SARS-CoV-2 m-RNA. To the best of our knowledge, this represents the first documented case in Colombia of immune thrombocytopenic purpura associated with mRNA vaccines (BNT162b2 or mRNA-1273), with a comprehensive 2-year clinical follow-up. Case Description: The patient received the initial and second doses of the mRNA BNT162b2 vaccine in June 2021, the first booster dose in November 2021 (mRNA-1273), and the second booster dose (mRNA BNT162b2) in June 2022. Thrombocytopenia (<100 x109 platelets/L, which is the criterion to define immune thrombocytopenic purpura) was documented after the second vaccination dose and both boosters, and it improved after corticosteroid therapy. However, cycling thrombocytopenia persisted until the clinical follow-up in August 2023, with platelet count ranging from 57 to 191 x109 platelets/L (mean: 103 x109 platelets/L). Conclusion: Given that secondary immune thrombocytopenic purpura can occur following SARS-CoV-2 mRNA vaccination, systematic research to identify risk factors associated with immune thrombocytopenic purpura due to COVID-19 immunization should be conducted.
How to cite this article: Lozada Ramos Heiler, Martínez-Vega Ruth Aralí, García Liliana Torcoroma. Immune thrombocytopenic purpura following mRNA-SARS-CoV-2 vaccination: A case report. Revista Cuidarte. 2024;15(2):e3799. https://doi.org/10.15649/cuidarte.3799
References
Instituto Nacional de Salud. Situación COVID-19. Boletín Epidemiológico Semanal. 2023;52:17. https://doi.org/10.33610/23576189.2023.52
World Health Organization 2023 data.who.int. WHO Coronavirus (COVID-19) dashboard >Vaccines [Internet]. Ginebra: WHO. [cited 2024 May 11]. Available from: https://data.who.int/dashboards/covid19/vaccines
Alshammari F, Abuzied Y, Korairi A, Alajlan M, Alzomia M, AlSheef M. Bullous pemphigoid after the second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report. Ann Med Surg (Lond). 2022;75:103420. https://doi.org/10.1016/j.amsu.2022.103420
Hagihara M, Uchida T, Inoue M, Ohara S, Imai Y. Severe thrombocytopenia after COVID-19 mRNA vaccination. Rinsho Ketsueki. 2021;62(12):1684-1687. https://doi.org/10.11406/rinketsu.62.1684
King ER, Towner E. A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination. Am J Case Rep. 2021;22:e931478. https://doi.org/10.12659/AJCR.931478
Leone MC, Canovi S, Pilia A, Casali A, Depietri L, Fasano T, et al. Four cases of acquired hemophilia A following immunization with mRNA BNT162b2 SARS-CoV-2 vaccine. Thromb Res. 2022;211:60-62. https://doi.org/10.1016/j.thromres.2022.01.017
Sato K, Anayama M, Sumi M, Kobayashi H. Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination. Rinsho Ketsueki. 2021;62(12):1688-1693. https://doi.org/10.11406/rinketsu.62.1688
Kuter DJ. The treatment of immune thrombocytopenia (ITP): focus on thrombopoietin receptor agonists. Ann Blood. 2021;6:7. http://dx.doi.org/10.21037/aob-21-23
Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR, Northern Region Haematology Group. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol. 2003;122:966-74. https://doi.org/10.1046/j.1365-2141.2003.04547.x
Lo E, Deane S. Diagnosis and classification of immune-mediated thrombocytopenia. Autoimmun Rev. 2014;13:577-83. https://doi.org/10.1016/j.autrev.2014.01.02
Lozada Ramos H, Martínez-Vega R, García LT. A case report of de novo immune thrombocytopenic purpura (ITP) following COVID-19-mRNA vaccination: 2-year clinical follow up. Mendeley Data, V2. 2024. https://doi.org/10.17632/wvdxt4r9yw.2
Waxman JG, Makov-Assif M, Reis BY, Netzer D, Balicer RD, Dagan N, et al. Comparing COVID-19-related hospitalization rates among individuals with infection-induced and vaccine-induced immunity in Israel. Nat Commun. 2022;13:2202. https://doi.org/10.1038/s41467-022-29858-5
Alameh MG, Weissman D, Pardi N. Messenger RNA-based vaccines against infectious diseases. Yu D, Petsch B. (eds) mRNA Vaccines. Curr Top Microbiol Immunol. 2022;440:111-145. https://doi.org/10.1007/82_2020_202
Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity, and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol. 2021;12:714170. https://doi.org/10.3389/fimmu.2021.714170
Cooper N, Ghanima W. Immune thrombocytopenia. N Engl J Med. 2019;381:945-955. https://doi.org/10.1056/NEJMcp1810479
Sivaramakrishnan P, Mishra M. Vaccination-associated immune thrombocytopenia possibly due to ChAdOx1 nCoV-19 (Covishield) coronavirus vaccine. BMJ Case Rep. 2022;15:e249237. https://doi.org/10.1136/bcr-2022-249237
Bidari A, Asgarian S, Pour Mohammad A, Naderi D, Anaraki SR, Gholizadeh Mesgarha M, et al. Immune thrombocytopenic purpura secondary to COVID‐19 vaccination: A systematic review. Eur J Haematol. 2023;110:335-353. https://doi.org/10.1111/ejh.13917
Saluja P, Amisha F, Gautam N, Goraya H. A Systematic Review of Reported Cases of Immune Thrombocytopenia after COVID-19 Vaccination. Vaccines. 2022;10(9):1444. https://doi.org/10.3390/vaccines10091444
Malayala SV, Mohan G, Vasireddy D, Atluri P. Purpuric rash and thrombocytopenia after the mRNA-1273 (Moderna) COVID-19 vaccine. Cureus. 2021;13(3):e14099. https://doi.org/10.7759/cureus.14099
Inagaki N, Kibata K, Tamaki T, Shimizu T, Nomura S. Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer. Lung Cancer. 2014;83(1):97-101. https://doi.org/10.1016/j.lungcan.2013.08.020
O'Shea KM, Aceves SS, Dellon ES, Gupta SK, Spergel JM, Furuta GT, et al. Pathophysiology of Eosinophilic Esophagitis. Gastroenterology. 2018;154(2):333-345. https://doi.org/10.1053/j.gastro.2017.06.065
Mohamed I, Abbas R, Amer A, Hassan E. Platelet/lymphocyte ratio (PLR) predictive value in immune thrombocytopenic purpura patients. Ain Shams Med J. 2023;74(1):13-20. https://doi.org/10.21608/ASMJ.2023.298369
Wang LH, Chen C, Wang Q, Song J, Cao J, Guo PX. Platelet to Lymphocyte Ratio and Glucocorticoid Resistance in Newly Diagnosed Primary Immune Thrombocytopenia: A Retrospective Cohort Study. Med Sci Monit. 2019;25:7321-7331. https://doi.org/10.12659/MSM.916907
Augène E, Lareyre F, Chikande J, Guidi L, Ballaith A, Bossert JN, et al. Platelet to lymphocyte ratio as a predictive factor of 30-day mortality in patients with acute mesenteric ischemia. PLoS One. 2019;14(7):e0219763. https://doi.org/10.1371/journal.pone.0219763
Published
How to Cite
Issue
Section
Categories
Altmetrics
Downloads
License
Copyright (c) 2024 Revista Cuidarte
This work is licensed under a Creative Commons Attribution 4.0 International License.
Journal Cuidarte, scientific publication of open access, is licensed under a Creative Commons Attribution (CC BY-NC), which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Any other form of use such as reproduction, transformation, public communication or distribution, for profit, requires the prior authorization of the University of Santander UDES.
The names and e-mail addresses entered in the Journal Cuidarte will be used exclusively for the purposes stated by this magazine and will not be available for any other purpose or other person.
The articles published in the Journal Cuidarte represent the criteria of their authors and do not necessarily constitute the official opinion of the University of Santander UDES.
